Insider Transactions in Q3 2024 at C4 Therapeutics, Inc. (CCCC)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 18
2024
|
Kendra Adams Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,837
-2.2%
|
$11,022
$6.38 P/Share
|
|
Sep 16
2024
|
Jolie Siegel Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
661
-1.21%
|
$3,966
$6.36 P/Share
|
|
Sep 16
2024
|
Jolie Siegel Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,250
+3.96%
|
-
|
|
Sep 16
2024
|
Kelly Schick Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
661
-1.21%
|
$3,966
$6.36 P/Share
|
|
Sep 16
2024
|
Kelly Schick Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,250
+3.96%
|
-
|
|
Sep 16
2024
|
Stewart Fisher Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
661
-0.5%
|
$3,966
$6.36 P/Share
|
|
Sep 16
2024
|
Stewart Fisher Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,250
+1.68%
|
-
|
|
Sep 16
2024
|
Kendra Adams Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
661
-0.78%
|
$3,966
$6.36 P/Share
|
|
Sep 16
2024
|
Kendra Adams Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,250
+2.6%
|
-
|
|
Sep 16
2024
|
Scott N Boyle Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
661
-1.21%
|
$3,966
$6.36 P/Share
|
|
Sep 16
2024
|
Scott N Boyle Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,250
+3.96%
|
-
|
|
Sep 16
2024
|
Andrew Hirsch President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,329
-1.53%
|
$19,974
$6.36 P/Share
|
|
Sep 16
2024
|
Andrew Hirsch President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+3.32%
|
-
|
|
Jul 10
2024
|
Leonard Reyno Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,191
-6.32%
|
$30,955
$5.0 P/Share
|
|
Jul 01
2024
|
Kenneth Carl Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,320
+1.98%
|
$9,280
$4.85 P/Share
|
|
Jul 01
2024
|
Donna Roy Grogan Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,836
+9.68%
|
$11,344
$4.85 P/Share
|